Successful use of recombinant FVIIa (Novoseven®) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukaemia and acquired FVII deficiency [3]

British Journal of Haematology

Volumn 106, Issue 1, 1999, Pages 254-255

  White, B ^a   Martin, M ^a   Kelleher, S ^a   Browne, P ^a   McCann, S R ^a   Smith, O P ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Aspergillus; Haemorrhage; Leukaemia; Recombinant FVIIa

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CYTARABINE; DAUNORUBICIN; FLUDARABINE; IDARUBICIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TIOGUANINE; VITAMIN K GROUP;

ACUTE GRANULOCYTIC LEUKEMIA; ASPERGILLOSIS; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD CLOTTING TIME; CHEMOTHERAPY; CLINICAL FEATURE; DRUG EFFICACY; HUMAN; LETTER; LUNG HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; TREATMENT INDICATION;

ACUTE DISEASE; ASPERGILLOSIS; FACTOR VII DEFICIENCY; FACTOR VIIA; HEMORRHAGE; HUMANS; LEUKEMIA, MYELOID; LUNG DISEASES; RECOMBINANT PROTEINS;

EID: 0032838415     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01562.x     Document Type: Letter

References (7)